Shares of Champions Oncology Inc (NASDAQ:CSBR) have been given an average recommendation of “Buy” by the six analysts that are covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $13.13.
Several brokerages have issued reports on CSBR. Roth Capital began coverage on Champions Oncology in a research report on Friday, September 20th. They set a “buy” rating and a $9.25 target price on the stock. Benchmark began coverage on Champions Oncology in a research report on Monday. They set a “buy” rating on the stock. Zacks Investment Research raised Champions Oncology from a “sell” rating to a “hold” rating in a research report on Tuesday, September 24th. Janney Montgomery Scott cut Champions Oncology from a “buy” rating to a “neutral” rating in a research report on Wednesday, July 24th. Finally, ValuEngine raised Champions Oncology from a “hold” rating to a “buy” rating in a research report on Wednesday, October 2nd.
Institutional investors have recently bought and sold shares of the company. Wedge Capital Management L L P NC acquired a new stake in shares of Champions Oncology in the 2nd quarter worth $277,000. Alambic Investment Management L.P. lifted its position in Champions Oncology by 27.0% during the 2nd quarter. Alambic Investment Management L.P. now owns 68,681 shares of the biotechnology company’s stock worth $538,000 after acquiring an additional 14,614 shares during the period. River & Mercantile Asset Management LLP acquired a new stake in Champions Oncology during the 2nd quarter worth about $1,082,000. BlackRock Inc. lifted its position in Champions Oncology by 12.0% during the 2nd quarter. BlackRock Inc. now owns 137,027 shares of the biotechnology company’s stock worth $1,073,000 after acquiring an additional 14,733 shares during the period. Finally, Wells Fargo & Company MN lifted its position in Champions Oncology by 110.4% during the 2nd quarter. Wells Fargo & Company MN now owns 149,100 shares of the biotechnology company’s stock worth $1,167,000 after acquiring an additional 78,250 shares during the period. 50.23% of the stock is owned by hedge funds and other institutional investors.
Champions Oncology (NASDAQ:CSBR) last announced its earnings results on Monday, September 16th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.09). The company had revenue of $6.74 million for the quarter, compared to the consensus estimate of $7.50 million. Champions Oncology had a negative net margin of 3.61% and a negative return on equity of 48.07%. On average, research analysts predict that Champions Oncology will post 0.01 earnings per share for the current year.
About Champions Oncology
Champions Oncology, Inc develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice.
See Also: Book Value Per Share in Stock Trading
Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.